Light-Activated Ruthenium-Arene Anticancer Drugs

  • ChemPubSoc Europe Logo
  • Author: ChemBioChem
  • Published Date: 03 June 2019
  • Source / Publisher: ChemBioChem/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
thumbnail image: Light-Activated Ruthenium-Arene Anticancer Drugs

Related Societies

Modern cancer therapies still suffer from problems such as the side-effects associated with chemotherapies or drug resistances. Thus, considerable efforts have been directed towards the development of anticancer drugs with new modes of action. One class of compounds with a high potential for cancer therapy are organometallic ruthenium(II) complexes of the type [Ru(η6-arene)(pta)Cl2] (arene = p-cymene, toluene, benzene, etc.; pta = 1,3,5-triaza-7-phosphaadamantane), the so-called RAPTA-type complexes.


Gilles Gasser, Chimie ParisTech, PSL University, France, Paul J. Dyson, Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland, and colleagues have designed a photoactive RAPTA-type complex (pictured). Instead of chloro ligands, the complex bears azide ligands for photoactivated chemotherapy (PACT). The complex was synthesized from Ru(η6-p-cymene)Cl2]2 by adding N3SiMe3 and pta.


The resulting diazide complex, [Ru(η6-p-cymene)pta(N3)2], was found to be inert in water in the dark. It slowly releases the azide ligand on exposure to light. Thanks to this property, the complex was found to have an anticancer effect upon light irradiation on human cervical carcinoma (HeLa) cells. The compound is about 1.2–1.4 times more toxic for the cancerous cell line HeLa than for a non-cancerous cell line. This could open up new uses of such RAPTA-type complexes in medicine.


 

Article Views: 840

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH